Guanylated Hyperbranched Polylysines with High In Vitro and In Vivo Antifungal Activity

Abstract With the rapid growth of fungal infections and the emergence of multi‐drug resistant (MDR) fungal strains, new antifungals with novel mechanisms are a pressing need to tackle this emerging health problem. Herein it is reported for the first time that hyperbranched polylysine (HPL) shows antifungal activities against Candida , especially for drug‐sensitive and MDR C. albicans strains, and broad‐spectrum antibacterial activities against both Gram‐negative and Gram‐positive bacteria. The high antimicrobial activities are ascribed to the high charge density and compact size of the globular structure of HPL. The in vitro antifungal activities of HPL3 are further enhanced by the modification of amine groups to form guanylated polylysines (HPL3‐Gxs). Similar to antimicrobial peptides (AMPs), HPLs and HPL3‐Gxs interact with and lyse the membranes of microbes, which mitigates the emergence of drug resistance. HPLs and HPL3‐Gxs demonstrate excellent in vivo antimicrobial efficacies against both lethal C. albicans challenge in the invasive candidiasis model and lethal Methicillin resistant Staphylococcus aureus challenge in the peritonitis model, and have potentials as broad‐spectrum antimicrobials.